Soft tissue implant sales set to nearly double in next three years
This article was originally published in Clinica
With an expected annual growth rate averaging 14-20% over the next few years, US sales of soft tissue implants (STI) are set to increase by almost 90% on current figures to exceed $700 million by 2002, predicts a new Theta report. These figures reflect the huge sales potential and growth within the STI market for companies to exploit innovative technologies and establish firm competitive positions.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.